2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). (September 2015) - Sobrero, A.F.; Price, T.J.; Cervantes, A.; Ducreux, M.; Andre, T.; Lordick, F.; Punt, C.J.; Hechmati, G.; Demonty, G.; Koukakis, R.; Peeters, M.